News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Clinical - Phase II
aTyr Pharma Receives U.S. FDA Orphan Designation For Resolaris 4/27/2015
VentiRx Pharmaceuticals, Inc. Granted Orphan Drug Designation In The European Union For Motolimod In The Treatment Of Ovarian Cancer 4/27/2015
Celsion Corporation (CLSN) Announces Appointment Of Harriet Shelare To Director, Communications 4/27/2015
Achillion (ACHN) Presents Detailed Clinical Results On ACH-3102 And ACH-3422 At The International Liver Congress 4/27/2015
Eiger Biopharma Announces Interim Results Of Lonafarnib In Combination With Ritonavir Or Pegylated Interferon In Patients Infected With Hepatitis Delta Virus (HDV) 4/27/2015
Imperial Innovations Release: Autifony Therapeutics Recruits First Patient Into Phase IIa Trial For Age Related Hearing Loss 4/27/2015
NeuroVive: FIrst Patient Enrolled In Clinical Phase II Study For Kidney Protection During Heart Surgery 4/27/2015
Celladon (CLDN) Reports Negative Results For CUPID2 Trial Of MYDICAR In Advanced Heart Failure 4/27/2015
Gilead (GILD) Announces Results From Studies Evaluating Sofosbuvir-Based Regimens In Chronic Hepatitis C Patients With Genotypes 2-5 4/27/2015
Celladon (CLDN) Will Lay Off Workers, Loses 80% of Value As Heart Failure Drug Flunks Phase IIb Trial 4/27/2015
Merck & Co. (MRK) Poised To Enter Oral HCV Market Dominated by Gilead (GILD) and AbbVie (ABBV) 4/24/2015
Amgen (AMGN) Boasts 51% Rise in Profit, Abandons Phase II Brodalumb Study, but Pushes Biosimilars 4/24/2015
Baseline Characteristics Of 228 Subjects Enrolled In MediciNova, Inc.'s Phase IIb Trial Of MN-166 (Ibudilast) In Progressive MS Presented At The American Academy of Neurology 67th Annual Meeting 4/24/2015
FDA Grants Orphan Drug Designation For DCR-PH1, Dicerna (DRNA)’s Investigational Therapy For The Treatment Of Primary Hyperoxaluria Type 1 (PH1) 4/24/2015
Merck & Co. (MRK) Announces Results From Phase 2/3 Study Of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir In Patients With Advanced Chronic Kidney Disease 4/23/2015
Gilead (GILD)’s Harvoni And Sovaldi Demonstrate Efficacy And Safety Among Chronic Hepatitis C Patients With Advanced Liver Disease 4/23/2015
Merck & Co. (MRK) Touts Results From C-SURFER Phase II/III Clinical Trial 4/23/2015
Ultragenyx Pharmaceuticals (RARE) Granted Additional Orphan Drug Designations For Triheptanoin 4/23/2015
Debiopharm Initiates Clinical Phase II Study Evaluating Debio 1450 In Staphylococcal Skin Infections 4/23/2015
Conatus Pharma Clinical Results At EASL Meeting Support Emricasan Registration Pathway In NASH 4/23/2015
Intercept Ltd. Announces New FLINT Trial Data Showing OCA Treatment Increases Fibrosis Resolution And Cirrhosis Prevention In High-Risk NASH Patients 4/23/2015
Mitotech Announces Phase 2 Data Showing Positive Effect Of SkQ1 In Patients With Dry Eye Syndrome 4/23/2015
Teva (TEVA) And Active Biotech AB (BTPC) Announce First Patient Enrolled In Phase II Study Evaluating Laquinimod For Primary Progressive MS 4/23/2015
Roche (RHHBY) Still Bullish on Alzheimer’s Research After Biogen (BIIB)’s Successful Clinical Trial 4/22/2015
FDA, Genervon and ALS Blogger Battle Over Clinical Trial Interpretation 4/22/2015
Ultragenyx Pharmaceuticals (RARE) Announces Positive Data From Investigator-Sponsored Trial Of Triheptanoin In Glucose Transporter Type-1 Deficiency Syndrome 4/22/2015
OncoMed Pharmaceuticals, Inc. (OMED) Initiates Dosing In Randomized Phase 2 Clinical Trial Of Demcizumab In Pancreatic Cancer Patients 4/22/2015
Genocea Biosciences Completes Enrollment In Phase IIa Human Challenge Study Of GEN-004 For The Prevention Of Infection By Pneumococcus 4/22/2015
Biothera’s Investigational Cancer Immunotherapy Alleviates Immune Suppression By Regulatory T Cells, Enabling CD4 And CD8 T Cell Proliferation, Study Finds 4/22/2015
GlobeImmune, Inc. (GBIM) Announces Opening Of Randomized Phase 2 Chordoma Trial At National Cancer Institute 4/22/2015
Nuvo Research Inc. (NRI.TO) Announces New WF10 Phase 2 Trial 4/22/2015
Lightlake Therapeutics Inc. (LLTP) Announces Adapt Pharma Limited Successfully Completed Intranasal Naloxone Study 4/22/2015
Viralytics Ltd (VLA.AX) Update On CALM And STORM Clinical Trials At AACR Annual Meeting 4/22/2015
Pharmaleads Announces The Inclusion Of The First Patient In Phase IIa Study Of Oral PL37 For Pain In Diabetic Neuropathy 4/22/2015
SCRA Technology Ventures Company Shares Phase 2 Results 4/22/2015
Alnylam (ALNY)'s Phase II Study Confirms Effectiveness of RNAi Drugs 4/21/2015
BrainStorm Cell Therapeutics Inc. Says Stem Cell Drug Benefits ALS Patients in Mid-Stage Trial 4/21/2015
Alnylam (ALNY) Reports 12-Month Clinical Data From Phase 2 Open Label Extension (OLE) Study Of Patisiran, An Investigational Rnai Therapeutic For Patients With Familial Amyloidotic Polyneuropathy (FAP) 4/21/2015
Argos Therapeutics, Inc. (ARGS) Announces Publication Of Data From Phase 2 Clinical Trial Of AGS-003 Fully Personalized Immunotherapy For Treatment Of Metastatic Renal Cell Carcinoma (mRCC) 4/21/2015
Genzyme (GENZ) Initiates Phase 2a Clinical Trial To Evaluate Oral Therapy For Fabry Disease 4/21/2015
NeuroVive: Clinical Phase II Study With Neurostat For Traumatic Brain Injury Passes Safety Evaluation 4/21/2015
Biothera’s Imprime PGG Cancer Immunotherapy Drug Candidate Shows Potential To Enhance Efficacy Of Immune Checkpoint Inhibitors 4/21/2015
Biothera’s Imprime PGG Investigational Immunotherapy Drug Modulates The Function Of Macrophages And Dendritic Cells To Drive Expansion Of Anti-Cancer T Cells 4/21/2015
New Data Demonstrate Potential Of Biothera’s Investigational Cancer Immunotherapy To Re-Orient The Tumor Microenvironment To Facilitate Greater Anti-Tumor Activity 4/21/2015
Biothera’s Investigational Cancer Immunotherapy Drug Imprime PGG Elicits Dramatic Expansion Of Cytotoxic T Cells 4/21/2015
Patients With Advanced Breast, Lung, Esophageal, And Colorectal Cancers Respond To Immunomedics, Inc. (IMMU)' Novel Antibody-Directed Chemotherapy After Failing Multiple Prior Standard Treatments 4/20/2015
Genticel To Present Further Promising Pharmacology In-Vivo Results Of Its Phase 2 Immunotherapeutic Vaccine Candidate, GTL001 (Procervix), At AACR Annual Meeting 2015 4/20/2015
FDA Grants Fast Track Designation To Eiger Biopharma's Lonafarnib For Hepatitis Delta Virus (HDV) Infection 4/20/2015
Anika Therapeutics (ANIK)' Cingal 13-02 Study Meets Primary Endpoint 4/20/2015
Published Phase 2 Results Demonstrate Neuraltus Pharmaceuticals, Inc.'s NP001 Potential Efficacy And Safety In ALS 4/20/2015
Pluristem Therapeutics (PSTI)'s Clinical Advisory Board Prepares Phase II Clinical Trials In Critical Limb Ischemia In Europe And Japan 4/20/2015
Atara Biotherapeutics (ATRA)' Collaborating Investigators' Abstract On T-Cell Therapy For EBV Lymphoma To Be Presented At A Clinical Trials Plenary Session At The American Association for Cancer Research Annual Meeting 2015 Is Now Available 4/20/2015
Otonomy, Inc. (OTIC) Completes Enrollment Of OTO-104 Multiple-Dose Safety Study In Meniere's Disease Patients 4/20/2015
EBV-CTL Clinical Trial Data Presented By Atara Biotherapeutics' Collaborating Investigators At A Plenary Session At The AACR Annual Meeting 2015 4/20/2015
Bionomics Limited (BNO.AX) Initiates Phase II Clinical Trial Of BNC210 For Treatment Of Anxiety 4/20/2015
Nymox Pharmaceutical (NYMX) Announces New Prostate Cancer Clinical Trial Results 4/20/2015
DelMar Pharmaceuticals Presents Updated Clinical Data On Phase I/II Study Of VAL-083 In Refractory Glioblastoma Multiforme (GBM) 4/20/2015
Immunocore Limited Announces Positive Clinical Trial Data For Novel First-in-Class Immunotherapy At AACR Annual Meeting 2015 4/20/2015
Can-Fite BioPharma (CFBI) Applies For Orphan Drug Designation In Europe For CF102 In The Treatment Of Liver Cancer 4/20/2015
Opexa Therapeutics (OPXA) Invited To Present Biomarker Data From NMO Patients At The American Academy of Neurology 2015 Annual Meeting 4/20/2015
Halozyme Therapeutics, Inc. (HALO) Presents New Preclinical Data At AACR Annual Meeting, Announces Clinical Data Presentation At ASCO 4/20/2015
Kamada Ltd. (KMDA) Reports Additional Data From European Phase 2/3 Clinical Study Of Inhaled Alpha-1 Antitrypsin To Treat AAT Deficiency 4/20/2015
Pharmacyclics (PCYC) Release: IMBRUVICA (ibrutinib) Longer-Term Follow-Up Data Demonstrate Durable Responses, Including Complete Responses, In Patients With Chronic Lymphocytic Leukemia (CLL) 4/20/2015
Bristol-Myers Squibb (BMY) Release: First Randomized Study Evaluating Opdivo (Nivolumab)+Yervoy (Ipilimumab) Regimen Demonstrates Superior Efficacy Versus Yervoy Alone In Patients With Previously Untreated Advanced Melanoma 4/20/2015
Discovery Laboratories (DSCO) Ceasing Production of Lead Drug Surfaxin, Chops 50% Employees 4/17/2015
Athersys (ATHX) Craters as Stem Cell Therapy Fails Phase II Stroke Study 4/17/2015
Targacept (TRGT) Winces As Last Remaining Drug Candidate Flops in Phase II Trial 4/17/2015
RXi Pharmaceuticals (RXII) Receives Orphan Drug Designation For Samcyprone From The U.S. FDA For The Treatment Of Malignant Melanoma Stage IIb to IV 4/17/2015
Bionomics Limited (BNO.AX) Showcases Oncology Drug Development Programs At 2015 American Association for Cancer Research Annual Meeting 4/17/2015
Athersys (ATHX) Announces Results From Phase 2 Study Of Multistem Cell Therapy For Treatment Of Ischemic Stroke 4/17/2015
Anika Therapeutics (ANIK) Reports On Cingal 13-01 Study Clinical Trial Top Line Data And Announces The Completion Of Cingal 13-02 Study’s Patient Enrollment 4/17/2015
Burzynski Research Institute Announces Publication Of Phase II Results In Patients With Non-Diffuse Intrinsic Pontine Glioma 4/17/2015
Ariad (ARIA) Presents Updated Clinical Data On Brigatinib In Patients With ALK+ Non-Small Cell Lung Cancer 4/17/2015
Aldeyra Therapeutics (ALDX) Announces First Patient Enrolled In Noninfectious Anterior Uveitis Phase II Clinical Trial 4/16/2015
Receptos (RCPT) Reports Positive Results For The Maintenance Period Of The Phase 2 TOUCHSTONE Trial Of Ozanimod In Ulcerative Colitis 4/16/2015
StemCells (STEM) Completes Enrollment Of First Cohort In Phase II Pathway Study For Cervical Spinal Cord Injury 4/16/2015
EMD Serono Highlights Scientific Commitment To MS With Data Presented At The American Academy of Neurology Annual Meeting 4/16/2015
FDA Grants Fast Track Designation For MediciNova, Inc.'s MN-001 (Tipelukast) For The Treatment Of NASH With Fibrosis 4/16/2015
Celgene (CELG) Release: Phase II Data For Apremilast In Behçet’s Disease Published In The New England Journal of Medicine 4/16/2015
DelMar Pharmaceuticals Adds Fourth Clinical Trial Site In Phase I/II Multicenter Study Of VAL-083 For Recurrent Malignant Glioma 4/16/2015
Biogen (BIIB) Shoots Up Following Positive Eye Drug RENEW Trial Data 4/15/2015
Biogen (BIIB) Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair 4/15/2015
Replicel Life Sciences Receives Approval To Conduct Clinical Trial For Patients With Chronic Achilles Tendinosis 4/15/2015
Biogen (BIIB) Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair 4/15/2015
Celsion Corporation (CLSN) Announces Positive Interim Data From Its Phase 2 DIGNITY Study In Breast Cancer 4/15/2015
Biothera Immunotherapy Combination Results In Tumor Reduction During Maintenance Phase Of Non-Small Cell Lung Cancer Study 4/15/2015
Bayer HealthCare (BAY) Devises Phase III Plans for Top Prospect 4/14/2015
Puma Biotechnology (PBYI) Expands Cohort In Phase II Trial Of PB272 In HER2 Mutation Positive Cancer Patients 4/14/2015
Clear Guide Medical Receives $1.5 Million NIH Funding To Make Ultrasound-Guided Procedures Easier 4/14/2015
Prolong Pharmaceuticals Presents Data On Unique "Un-Sickling" In Vitro Activity Observed In Sickle Cell Investigational Drug SANGUINATE 4/14/2015
GeoVax Labs Inc. (GOVX.OB) To Seek Dual Pathway For Advancing Its HIV Preventive Vaccine 4/14/2015
Pharmalink AB Phase II Trial Of Nefecon Halted Early 4/14/2015
Mechanism Of Action Of ABIVAX's First-in-class Anti-HIV Drug Published Today In Peer-Reviewed Journal Retrovirology 4/13/2015
Versartis, Inc. (VSAR) Initiates Phase 2/3 Trial Of VRS-317 In Japan For Children With Growth Hormone Deficiency 4/13/2015
Rheonix, Inc. Receives $1.5 Million SBIR Phase II Grant From The National Institute Of Dental And Craniofacial Research Of The NIH To Complete Development Of A Rapid Point-Of-Care Test For HIV/AIDS 4/13/2015
ARCA biopharma Receives FDA Fast Track Designation For Gencaro Atrial Fibrillation Development In A Genetically Targeted Heart Failure Population 4/13/2015
Arrowhead Research Corporation (ARWR) Cleared To Proceed With Multiple Dose Phase 2b Study Of ARC-520 4/13/2015
Merck & Co. (MRK) Breathes a Sigh of Relief as the FDA Calls Hepatitis C Drugs a Breakthrough 4/10/2015
Will AbbVie (ABBV)'s HCV Candidates Threaten Gilead (GILD)? 4/10/2015
Admedus Herpes Phase II – First Dosing To Commence 4/10/2015
EXCLUSIVE: Collaboration to Find Pancreatic Cancer Biomarker Could See Lead Candidate by 2018, Says Berg CTO 4/9/2015
Recro Pharma (REPH) Announces Update On On-Going Phase II Clinical Trial Of Dex-IN For Treatment Of Acute Pain On Day 1 Following Surgery 4/9/2015
Dermira Doses First Patient In DRM01 Phase IIb Acne Trial 4/9/2015
BioBlast Pharma (ORPN) Announces Granting Of Fast Track Designation By The FDA For Cabaletta In Oculopharyngeal Muscular Dystrophy (OPMD) 4/9/2015
Shire (SHPGY) Reports Topline Results From First Of Three Placebo-Controlled Phase 2 Studies Of SHP625 (LUM001) In Children With Alagille Syndrome 4/9/2015
Pharmacyclics (PCYC) Release: New Longer-Term IMBRUVICA (ibrutinib) Data Show High Response Rates In Patients With Waldenstrom's Macroglobulinemia 4/9/2015
Onxeo Release: Belinostat Phase I/II Results In Soft Tissue Sarcoma To Be Presented At The 2015 Annual ASCO Meeting 4/9/2015
Rhythm Initiates Phase 2b Clinical Trial Of Relamorelin For Diabetic Gastroparesis 4/8/2015
Regulus Therapeutics, Inc. (RGLS) Release: RG-125 (AZD4076), A microRNA Therapeutic Targeting Microrna-103/107 For The Treatment Of NASH In Patients With Type 2 Diabetes/Pre-Diabetes, Selected As Clinical Candidate By Astrazeneca 4/8/2015
Capricor Therapeutics, Inc. Completes Enrollment Of Initial Phase Of DYNAMIC Clinical Trial Of Cardiosphere-Derived Cell Therapy For Treatment Of Advanced Heart Failure 4/8/2015
BioSpecifics Technologies Corporation (BSTC) To Present At The 14th Annual Needham Healthcare Conference 4/8/2015
Athersys, Inc. (ATHX) Phase 2 Ischemic Stroke Clinical Trial Results To Be Presented At European Stroke Conference 4/8/2015
Prolong Pharmaceuticals' Flagship Product SANGUINATE Granted Orphan Drug Designation By The FDA 4/8/2015
DiscoveryBioMed Is Awarded A New Phase II SBIR Grant Award To Develop New Medicines To Fight The Diabetes And Obesity Epidemic In The U.S. And Globally 4/8/2015
Clovis Oncology (CLVS) Shares Leap as FDA Deems Ovarian Cancer Drug a Breakthrough, Company Preps for ARIEL3 4/8/2015
Clovis Oncology (CLVS) Receives Breakthrough Therapy Designation For Rucaparib For Monotherapy Treatment Of Advanced Ovarian Cancer In Patients With BRCA-Mutated Tumors (Inclusive Of Both Germline And Somatic BRCA Mutations) 4/7/2015
Benitec, Inc. (BLT.AX) Provides Update On TT-034 Trial 4/7/2015
Delcath Systems, Inc. (DCTH) Adds New U.S. Center To Global Phase 2 Hepatocellular Carcinoma Program 4/7/2015
YPrime Awarded Global Phase II Oncology Clinical Trial Which Will Utilize Proprietary eClinical Supply Forecasting Tool Combined With IRT 4/7/2015
Celldex (CLDX)' Phase 2 EMERGE Study Of Glembatumumab Vedotin In Metastatic Breast Cancer Published In Journal Of Clinical Oncology 4/7/2015
Progenics Pharmaceuticals, Inc. (PGNX) Announces The Initiation Of Fuji's Phase 2 Trial For 1404 In Japan 4/7/2015
Celtaxsys, Inc. Has Regulatory Clearance To Begin Phase 2 Trial Of Oral CTX-4430 Anti-Inflammatory Therapy For Moderate To Severe Acne Vulgaris - Recruitment Of Patients To Commence Immediately 4/7/2015
Alkermes (ALKS) Announces Positive Topline Results From Complete Six-Month Phase 2 Clinical Trial Of ALKS 3831 In Schizophrenia 4/6/2015
Neurotrope Selects Worldwide Clinical Trials To Commence Services For Phase 2B Trial Of Bryostatin For The Treatment Of Alzheimer's Disease 4/6/2015
Advaxis, Inc. And RTOG Foundation To Collaborate On Pivotal Phase 2/3 Clinical Trial Of ADXS-HPV In Anal Cancer 4/6/2015
AstraZeneca PLC (AZN)'s Failed Cancer Drug Finds New Life in Alzheimer’s Treatment 4/3/2015
Flexion (FLXN) CEO Discusses Pipeline and Jobs 4/3/2015
Replicor Announces Completion Of Enrollment In Phase II Trial 4/3/2015
Clementia Advances Phase 2 Clinical Trial Of Palovarotene In Fibrodysplasia Ossificans Progressiva Based On Recommendations From Data Monitoring Committee (DMC) 4/2/2015
Public Health Agency of Canada Release: Clinical Trials Prove Canada's VSV-EBOV Ebola Vaccine Safe And Effective 4/2/2015
Astellas Pharma Inc. (ALPMY) Release: Enzalutamide Demonstrates Statistically Significant Improvement In Progression Free Survival Compared With Bicalutamide In Strive Trial 4/2/2015
Ocera Therapeutics, Inc. (OCRX) Completes Interim Analysis Of OCR-002 In Phase 2b STOP-HE Study For The Treatment Of Acute Hepatic Encephalopathy 4/2/2015
Teva (TEVA) And Xenon Pharmaceuticals Inc. Announce Enrollment Of First Patient In A Phase 2b Study Evaluating TV-45070 For Postherpetic Neuralgia (PHN) 4/2/2015
Perosphere Inc. Receives FDA Fast Track Designation For Investigational Anticoagulant Reversal Agent PER977 4/2/2015
GeoVax Labs Inc. (GOVX.OB) Provides Update On Its HIV Vaccine Program 4/2/2015
SAGE Therapeutics Announces Positive End-Of-Phase 2 Meeting With FDA And Planned Initiation Of SAGE-547 Global Phase 3 Trial In Mid-2015 4/2/2015
ESSA Pharma Announces Filing Of Investigational New Drug Application For EPI-506 4/1/2015
NeuroDerm Ltd. (NDRM) To Announce Updated Topline Results Of Phase II Study Of Continuous, Subcutaneously-Delivered Levodopa/Carbidopa For The Treatment Of Parkinson's Disease At The 67th Annual Meeting Of The American Academy of Neurology 4/1/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015
Servier Initiates Phase 2 Study Of Gevokizumab In Patients With Diabetic Nephropathy 4/1/2015
NIH Funds Study Of Fully Personalized Immunotherapy AGS-004 Combined With A Latency Reversing Therapy For The Treatment Of HIV 4/1/2015
Pharmacyclics (PCYC) Release: Solid Tumor Study Investigating Ibrutinib (IMBRUVICA) In Combination With Anti-PD-L1 Antibody (MEDI4736) Commences In Patients With Relapsed/Refractory Non-Small Cell Lung, Breast And Pancreatic Cancers 4/1/2015
Hutchison Medipharma's Cancer Drug Meets Endpoint In Phase II Trial 4/1/2015
Anergis Announces Completion Of Treatment In AllerT Phase II Dose-Ranging Trial 4/1/2015
Burzynski Research Institute Announces Publication Of Phase II Results In Adults With Newly-Diagnosed Anaplastic Astrocytoma 4/1/2015
Kala Pharmaceuticals KPI-121 Meets Primary Sign Endpoint In Phase II For Dry Eye Disease 4/1/2015
RegeneRx Biopharmaceuticals, Inc. (RGRX)'s RGN-259 Meets Key Efficacy Objectives In Phase II Clinical Trial In Patients With Severe Dry Eye Reported In Current Issue Of Cornea 4/1/2015
Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation For STP-206 For Prevention Of Necrotizing Enterocolitis 4/1/2015
Capricor Therapeutics, Inc. Completes Enrollment Of Phase II Clinical Trial For Cenderitide To Treat Heart Failure 3/31/2015
BioTie Therapies Corp. Announces Start Of Patient Enrolment Into Phase IIa Clinical Study With BTT1023 In Primary Sclerosing Cholangitis 3/31/2015
Peregrine Pharmaceuticals, Inc. (PPHM) Announces Promising Bavituximab Phase I Data Published In The Peer-Reviewed Journal Cancer Medicine In Advanced Metastatic Breast Cancer 3/31/2015
Emisphere Technologies, Inc. (EMIS) Reports Fourth Quarter And Full Year 2014 Financial Results 3/31/2015
Intra-Cellular Therapies, Inc. Presents The ITI-007 Clinical Development Program At The 15th International Congress On Schizophrenia Research 3/31/2015
Ocata Therapeutics Successfully Completes Dosing In Phase 1/2 RPE Studies 3/31/2015
RedHill Biopharma Ltd. (RDHL) Acquires Phase II First-in-Class Oral Small Molecule SK2 Inhibitor From Apogee Biotech 3/31/2015
Can-Fite BioPharma (CFBI) PhII/III: CF101 Did Not Achieve Primary Endpoint 3/30/2015
Ohr Pharma (OHRP)'s OHR-102 Fails in Phase II, Shares Plunge 3/30/2015
GENFIT (ALGFT)'s GFT505 Misses Target in Phase IIB But Hopes to Proceed to Phase III 3/30/2015
Can-Fite BioPharma (CFBI) Files 2014 Annual Report On Form 20-F 3/30/2015
Synthetic Biologics, Inc. (SYN) Initiates Phase 2a Clinical Trial Of SYN-004 To Protect The Microbiome And Prevent C. Difficile 3/30/2015
Innate Pharma (IPH.PA ) : DSMB Recommends Continuation Of Effikir Trial With Two Arms 3/30/2015
CASI Pharmaceuticals  (CASI) Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3/30/2015
BioMarin (BMRN) Announces One Oral And 7 Poster Presentations At The 2015 American College Of Medical Genetics And Genomics Annual Clinical Genetics Meeting 3/30/2015
Conatus Pharma Shares Soar On Successful Emricasan Phase II Results 3/27/2015
Ohr Pharma (OHRP) Announces Final Topline Data From OHR-102 Phase II IMPACT Study In Wet-AMD 3/27/2015
Burzynski Research Institute Announces Publication Of Phase 2 Clinical Study In Metastatic Colon Adenocarcinoma Of The Liver 3/27/2015
PharmaCyte Biotech (NVLX) On Track to Commence Clinical Trials 3/27/2015
Proteon Therapeutics, Inc. (PRTO) Announces Positive Long-Term Results From Phase 2 Study Of Investigational New Drug Vonapanitase In Chronic Kidney Disease Patients Undergoing Surgical Creation Of An Arteriovenous Fistula For Hemodialysis 3/27/2015
NIH Release: Ebola Test Vaccines Appear Safe In Phase 2 Liberian Clinical Trial 3/27/2015
GENFIT (ALGFT) Announces Topline Results From The Golden-505 Trial In Nash 3/26/2015
Otonomy, Inc. (OTIC) Initiates Phase 2 Clinical Trial for AuriPro(TM) In Label Expansion Indication 3/26/2015
Galena Biopharma  (GALE) Expands Patient Population In NeuVax(TM) (nelipepimut-S) And Trastuzumab Phase 2b Combination Clinical Trial In HER2 1+/2+ Patients 3/26/2015
Conatus Pharmaceuticals Inc. Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial Of Emricasan 3/26/2015
Aldeyra Therapeutics (ALDX) Opens Enrollment In Noninfectious Anterior Uveitis Phase II Clinical Trial 3/26/2015
Apceth GmbH Initiates Phase II Clinical Trial For Pioneering Engineered Cell Therapy To Treat Gastrointestinal Cancer 3/26/2015
Amarantus BioSciences, Inc. Opens Investigational New Drug (IND) Application With The U.S. FDA Allowing The Start Of A Phase 2b Program Of Eltoprazine In Parkinson's Disease Levodopa-Induced Dyskinesia 3/26/2015
MorphoSys AG And Celgene (CELG) Mutually Agree To End MOR202 Collaboration 3/26/2015
Dermira Reports Fourth Quarter And Full Year 2014 Financial Results And Provides Corporate Update 3/26/2015
Cardio3 BioSciences Reports 2014 Financial And Operating Results 3/26/2015
Neothetics Reports Fourth Quarter and Full Year 2014 Financial Results 3/26/2015
CASI Pharmaceuticals  (CASI) Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China 3/25/2015
Agios Pharmaceuticals (AGIO) Announces Orphan Drug Designation Of AG-348 For Treatment Of Pyruvate Kinase Deficiency 3/25/2015
Lpath, Inc. (LPTN) Reports Results For ASONEP Phase 2a Study In Renal Cell Carcinoma 3/25/2015
Signum Dermalogix Out-Licenses SIG990 To Dermata Therapeutics For Topical Treatment of Rosacea 3/25/2015
Regulus Therapeutics, Inc. (RGLS) Receives Orphan Medicinal Product Designation From The European Commission (EC) For RG-012, A Microrna Therapeutic In Development For The Treatment Of Alport Syndrome 3/25/2015
VBL Therapeutics (VBLX) Reports Interim Topline Results From Phase 2 Clinical Trial Of VB-111 In Recurrent Glioblastoma (Rgbm) 3/25/2015
Cellular Biomedicine Group (CBMG) Announces Interim Results From Phase IIb Clinical Trial For Knee Osteoarthritis Stem Cell Rejoin Therapy 3/25/2015
Marinus Pharmaceuticals (MRNS)' Ganaxolone Receives FDA Orphan Drug Designation In PCDH19 Female Epilepsy 3/25/2015
TRANSGENE (ENX:TNG) Reports 2014 Financial Results And Outlines Promising Clinical Pipeline 3/25/2015
Mologen AG (MOLGF.PK): Start Of Pivotal Study For Cancer Immunotherapy MGN1703 Influences 2014 Annual Result 3/25/2015
Oncolytics Biotech Inc. (ONC.TO) Announces Receipt Of Orphan Drug Status From The European Medicines Agency For Ovarian Cancer 3/25/2015
Why Investors Shouldn't Freak Out Over Vertex (VRTX)'s Latest Trial Results 3/24/2015
Aldeyra Therapeutics (ALDX) Announces First Patient Enrolled In Sjogren-Larsson Syndrome Phase II Clinical Trial 3/24/2015
NGM Announces Positive Phase II Clinical Data In Primary Biliary Cirrhosis Patients For NGM282, A First-In-Class Investigational Medicine 3/24/2015
Pluristem Therapeutics (PSTI) Announces Key Strategic Objectives For Development Of PLX-R18 In Hematopoietic Indications 3/24/2015
MediGene AG (MDGEF.PK) Starts Phase I/II Study With DC Vaccine To Treat Acute Myeloid Leukaemia (AML) 3/24/2015
Astellas Pharma Inc. (ALPMY) And Medivation, Inc. (MDVN) Announce New Enzalutamide Data Presented During Plenary Presentations At The 2015 European Association Of Urology Congress 3/24/2015
Soligenix (SNGX) Announces Recent Accomplishments And Year-End 2014 Financial Results 3/24/2015
GenVec Inc. (GNVC) Reports Fourth Quarter And 2014 Year-End Financial Results 3/24/2015
Mast Therapeutics (MSTX) Reports Fourth Quarter And Full Year 2014 Financial Results 3/24/2015